Fenofibrate-induced decrease of expression of CYP2C11 and CYP2C6 in rat

Biopharmaceutics and Drug Disposition

Volumn 32, Issue 8, 2011, Pages 482-487

  Večeřa, Rostislav ^a   Zachařová, Alice ^a   Orolin, Jan ^a   Strojil, Jan ^a   Škottová, Nina ^a   Anzenbacher, Pavel ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

CYP2C11; CYP2C6; Cytochrome P450; Fenofibrate; Rat

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C11; CYTOCHROME P450 2C6; CYTOCHROME P450 2C9; DICLOFENAC; FENOFIBRATE; IBUPROFEN; MESSENGER RNA; UNCLASSIFIED DRUG; WARFARIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; FATTY LIVER; HYPERTRIGLYCERIDEMIA; LIVER MICROSOME; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; ENZYME REPRESSION; FENOFIBRATE; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; MALE; MICROSOMES, LIVER; RATS; RATS, WISTAR; STEROID 16-ALPHA-HYDROXYLASE; STEROID 21-HYDROXYLASE;

EID: 80054887991     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.774     Document Type: Article

References (35)

1. Touyz RM, Schiffrin EL. Peroxisome proliferator-activated receptors in vascular biology - molecular mechanisms and clinical implications. Vascul Pharmacol 2006; 45: 19-28. (Pubitemid 43963482)
2. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998; 34: 155-162. (Pubitemid 28077673)
3. Aldridge MA, Ito MK. Fenofibrate and warfarin interaction. Pharmacotherapy 2001; 21: 886-889. (Pubitemid 32606803)
4. Kim KY, Mancano MA. Fenofibrate potentiates warfarin effects. Ann Pharmacother 2003; 37: 212-215. (Pubitemid 36172861)
5. Yamazaki H, Shimada T. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. Biochem Pharmacol 1997; 54: 1195-1203. (Pubitemid 27497246)
6. Anzenbacher P, Anzenbacherová E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 2001; 58: 737-747. (Pubitemid 32553031)
7. Mo SL, Zhou ZW, Yang LP, Wei MQ, Zhou SF. New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab 2009; 10: 1075-1126.
8. Wang H, Cheng JD, Montgomery D, Cheng KC. Evaluation of the binding orientations of testosterone in the active site of homology models for CYP2C11 and CYP2C13. Biochem Pharmacol 2009; 78: 406-413.
9. Corton JCh, Fan LQ, Brown S, Anderson SP, Bocos C, Cattley RC. Down-regulation of cytochrome P450 2C family members and positive acute-phase response gene expression by peroxisome proliferator chemicals. Mol Pharmacol 1998; 54: 463-473. (Pubitemid 28442939)
10. Ogilvie BW, Zhang D, Li W, et al. Glucuronidation converts gemfibrozil to a potent, metabolismdependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 2006; 34: 191-197. (Pubitemid 43042661)
11. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 67-74. (Pubitemid 26425815)
12. Zhu X, Lee DY, Shin WG. Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. Biopharm Drug Dispos 2007; 28: 125-133. (Pubitemid 46730920)
13. Szutowski MM, Łukasik M, Wawer ZT, et al. In vivo effect of 5- and 8-methoxypsoralens and cimetidine on R, S-warfarin metabolism in rat. J Appl Toxicol 2002; 22: 327-332.
14. Doggrell SA. Inhibition of cardiac cytochrome P450: a new approach to cardiac ischaemia and reperfusion damage. Expert Opin Ther Targets 2004; 8: 491-493. (Pubitemid 39359653)
15. Iber H, Chen Q, Sewer M, Morgan ET. Regulation of hepatic cytochrome P450 2C11 by glucocorticoids. Arch Biochem Biophys 1997; 345: 305-310. (Pubitemid 27400624)
16. Gerbal-Chaloin S, Daujat M, Pascussi JM, Pichard-Garcia L, Vilarem MJ, Maurel P. Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J Biol Chem 2002; 277: 209-217. (Pubitemid 34952047)
17. Ripp SL, Falkner KC, Pendleton ML, Tamasi V, Prough RA. Regulation of CYP2C11 by dehydroepiandrosterone and peroxisome proliferators: identification of the negative regulatory region of the gene. Mol Pharmacol 2003; 64: 113-122. (Pubitemid 36763562)
18. Shaban Z, Soliman M, El-Shazly S, El-Bohi K, Abdelazeez A, Kehelo K. AhR and PPARalpha: antagonistic effects on CYP2B and CYP3A, and additive inhibitory effects on CYP2C11. Xenobiotica 2005; 35: 51-68. (Pubitemid 40459217)
19. Gatica A, Aguilera MC, Contador D, Loyola G, Pinto CO, Amigo L. P450 CYP2C epoxygenase and CYP4A omega-hydroxylase mediate ciprofibrate-induced PPARalpha-dependent peroxisomal proliferation. J Lipid Res 2007; 48: 924-934. (Pubitemid 46557897)
20. Daniel WA, Haduch A, Syrek M, Boksa J. Direct and indirect interactions between antidepressant drugs and CYP2C6 in the rat liver during longterm treatment. Eur Neuropsychopharmacol 2006; 16: 580-587. (Pubitemid 44716661)
21. Yang KH, Choi YH, Lee U, Lee JH, Lee MG. Effects of cytochrome P450 inducers and inhibitors on the pharmacokinetics of intravenous furosemide in rats: involvement of CYP2C11, 2E1, 3A1 and 3A2 in furosemide metabolism. J Pharm Pharmacol 2009; 61: 47-54.
22. Dvorak Z, Modriansky M, Pichard-Garcia L, et al. Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol Pharmacol 2003; 64: 160-169. (Pubitemid 36759828)
23. Ohhira S, Enomoto M, Matsui H. Sex difference in the principal cytochrome P-450 for tributyltin metabolism in rats. Toxicol Appl Pharmacol 2006; 210: 32-38. (Pubitemid 41790548)
24. Klimes I, Vrána A, Kunes J, et al. Hereditary hypertriglyceridemic rat: a new animal model of metabolic alterations in hypertension. Blood Press 1995; 4: 137-142.
25. Škottová N, Kazdová L, Oliyarnyk O, Večeřa R, Sobolová L, Ulrichová J. Phenolics-rich extracts from Silybum marianum and Prunella vulgaris reduce a high-sucrose diet induced oxidative stress in hereditary hypertriglyceridemic rats. Pharmacol Res 2004; 50: 123-130. (Pubitemid 38737242)
26. Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension 1998; 31: 225-231.
27. Frederiksen KS, Wulf EM, Wassermann K, Sauerberg P, Fleckner J. Identification of hepatic transcriptional changes in insulin-resistant rats treated with peroxisome proliferator activated receptor-alpha agonists. J Mol Endocrinol 2003; 30: 317-329. (Pubitemid 36722621)
28. Chen YJ, Quilley J. Fenofibrate treatment of diabetic rats reduces nitrosative stress, renal cyclooxygenase-2 expression, and enhanced renal prostaglandin release. J Pharmacol Exp Ther 2008; 324: 658-663. (Pubitemid 351185835)
29. Staels B, Vu-Dac N, Kosykh VA, et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. J Clin Invest 1995; 95: 705-712.
30. Lupp A, Karge E, Hopf H, Machts H, Oelschlager H, Fleck Ch. Fibrates and their newly synthesized glycinate or glycinate-methylester derivatives: Comparison of the interactions with liver cytochrome P450 dependent monooxygenase- and oxidasefunctions in vitro. Exp Toxic Pathol 2003; 54: 433-440. (Pubitemid 36841189)
31. Liu A, Chen Y, Yang Z, Feng Y, Rui W, Luo W. New metabolites of fenofibrate in Sprague-Dawley rats by UPLC-ESI-QTOF-MS-based metabolomics coupled with LC-MS/MS. Xenobiotica 2009; 39: 345-354.
32. Ledl M, Hohenecker J, Francesconi C, Roots I, Bauer MF, Roden M. Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone. Diabetologia 2005; 48: 1996-1998. (Pubitemid 41416908)
33. Scollon EJ, Starr JM, Godin SJ, DeVito MJ, Hughes MF. In vitro metabolism of pyrethroid pesticides by rat and human hepatic microsomes and cytochrome P450 isoforms. Drug Metab Dispos 2009; 37: 221-228.
34. Ando Y, Fuse E, Figg WD. Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 2002; 8: 1964-1973. (Pubitemid 34633760)
35. McGinnity DF, ParkerAJ, Soars M, Riley RJ. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metab Dispos 2000; 28: 1327-1334.